Pharmacological Treatment for Heart Failure with Preserved Ejection Fraction

Understanding Heart Failure

Heart failure (HF) serves as a common endpoint for various health conditions, including cardiovascular, metabolic, and kidney diseases. It can be categorized based on the heart’s ejection fraction, which measures the percentage of blood ejected from the heart during each contraction. While treatment advancements for patients with reduced ejection fraction (HFrEF) have made significant progress, options for those with preserved ejection fraction (HFpEF) remain limited. Current clinical trials do not provide conclusive results for effective HFpEF treatments.

Research Insights from Northwestern University

Researchers at the Northwestern University Feinberg School of Medicine have examined large-scale multicenter clinical trials focused on HFpEF. Their findings highlight the pharmacological efficacy of available treatment strategies for this condition.

Pathophysiological Mechanisms of HFpEF

The pathophysiology of HFpEF is linked to a pro-inflammatory state that leads to coronary microvascular endothelial dysfunction. This dysfunction is characterized by reduced nitric oxide (NO) bioavailability, diminished cyclic GMP (cGMP)/protein kinase G (PKG) signaling, abnormalities in titin, and increased stiffness of cardiomyocytes. These factors contribute to a series of complications, including elevated left ventricle filling pressures, left atrial dysfunction, atrial fibrillation, pulmonary venous congestion, dyspnea, renal hypoperfusion, water retention, worsened pulmonary venous congestion, pulmonary hypertension, and right ventricular (RV) failure. Additionally, neurohormonal modulation plays a role in the efficacy of neurohormonal antagonists as a treatment strategy.

Potential Pharmacological Strategies

Angiotensin-converting enzyme (ACE) inhibitors may offer benefits for patients with HFpEF, particularly those dealing with comorbidities like diabetes, hypertension, and chronic kidney disease. Angiotensin-receptor blockers have also shown a reduction in HF hospitalizations, especially among patients with less severe HFpEF and lower natriuretic peptide levels.

Emerging evidence suggests that mineralocorticoid receptor antagonists could benefit patients with less severe forms of HFpEF and obesity-related HFpEF. In contrast, nitrates have not been shown to aid in HFpEF management, and digoxin is generally not recommended, although it may have positive effects in patients with pulmonary hypertension. Beta-blockers are commonly prescribed for HFpEF and have been associated with significant improvements in walking distance, though not in oxygen consumption.

Phosphodiesterase type 5 inhibitors may prove ineffective for most HFpEF patients, particularly those without severe left ventricular hypertrophy.

Novel Pharmacological Agents

Recent studies have explored several novel pharmacological agents for HFpEF treatment, including angiotensin receptor neprilysin inhibitor LCZ696, endothelin receptor antagonists (ERA), inorganic nitrate-nitrite compounds, sodium-glucose cotransporter-2 inhibitors (SGLT-2), soluble guanylate cyclase (sGC) stimulators, and riociguat. Research into the potential benefits of these new strategies is ongoing.

Conclusion

It is improbable that a single pharmacological agent will be universally effective for all patients within the heterogeneous HFpEF population. However, targeted therapies, akin to those used in cancer treatment, may prove beneficial for individuals with HFpEF syndrome.

Written By: Vagner Raso